CVD-related fatalities in individuals under 75 years old are on the rise in the U.K. for the first time in five decades, the Guardian reported May 12.

The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.

A machine learning algorithm can now predict death and MI more accurately than certified cardiologists, according to research presented at the International Conference on Nuclear Cardiology and Cardiac CT in Lisbon, Portugal, this May.

“The results of this research are extremely exciting, as it will significantly impact clinical care,” reported study author Mishal Mendiratta-Lala, MD, with the division of abdominal radiology at Michigan Medicine in Ann Arbor.

A team funded by the National Institutes of Health has succeeded in growing human acellular vessels—implantable, bioengineered human blood vessels—to replace damaged vasculature in patients with end-stage kidney failure.

South Korean researchers are working on packing the ability to monitor heart health and detect signs of atrial fibrillation into what might be the smallest cardiology wearable to date: a “smart ring.”

The bioresorbable vascular scaffold, once an exciting prospect for cardiologists, saw a unique rise and fall in popularity within a year of its introduction to the CV market.

Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.